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Abstract
Background: In the group of elderly patients (≥70 years) with metastatic pancreatic ductal adenocarcinoma
(mPDAC), it is not known who benefits from intensive 1st line nab-paclitaxel/gemcitabine (nab-p/gem) combination
chemotherapy or who would rather suffer from increased toxicity. We aim to determine whether treatment
individualization by comprehensive geriatric assessments (CGAs) improves functional outcome of the patients.
Methods/Design: GrantPax is a multicenter, open label phase 4 interventional trial. We use a CGA to stratify elderly
patients into three parallel treatment groups (n = 45 per arm): 1) GOGO (nab-p/gem), 2) SLOWGO (gem mono) or
3) FRAIL (best supportive care). After the 1st cycle of chemotherapy (or 4 weeks in FRAIL group) another CGA and
safety assessment is performed. CGA-stratified patients may not decline in their CGA performance in response to
the first cycle of chemotherapy (primary objective), measured as a loss of 5 points or less in Barthels activities of
daily living. Based on the second CGA, patients are re-assigned to their definite treatment arm and undergo further
CGAs to monitor the course of treatment. Secondary endpoints include CGA scores during the course of therapy
(CGA1–4), response rates, safety and survival rates.
Discussion: GrantPax is the first trial implementing a CGA-driven treatment to personalize therapy for elderly
patients with pancreatic cancer. This may lead to standardization of therapy decisions for elderly patients and may
optimize standard of care for this increasing group of patients.
Trial registration: NCT02812992, registered 24.06.2016.
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Background
In the developed countries, pancreatic cancer is the fifth
leading cause of cancer-related death [1]. Pancreatic adeno-
carcinomas usually show rapid progression and limited re-
sponse rates to chemotherapy, leading to a poor prognosis.
Hence, median survival of patients with metastasized dis-
ease is only three to six months [2].
The incidence of pancreatic cancer increases with age,
70% presenting over the age of 65 years [3]. In Germany,
mean age at diagnosis is 71 years in men and 75 years in
women [4]. Elderly patients differ in psychosocial, func-
tional and biological characteristics compared to younger
patients [5]. Specifically, differences in stem cell biology, the
functional decline of organs with age and significant
co-morbidities may lead to enhanced toxicities [6, 7]. How-
ever, elderly patients are a very heterogeneous group of pa-
tients, since the physiologic and medical changes of aging
are poorly reflected in chronologic age. There is rising evi-
dence that comprehensive geriatric assessments (CGAs) as
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well as condensed geriatric screening tools are able to pre-
dict treatment-related toxicity and outcome [6, 8–10]. In
addition to performance status, these tools improve the as-
sessment of co-morbidities, psychosocial and cognitive is-
sues and functional aspects, all of which can impact the
clinical course of elderly pancreatic cancer patients [6, 10].
Gemcitabine has been the standard chemotherapy for
first-line treatment of pancreatic adenocarcinomas but only
modestly increased median overall survival [11]. Recent
studies convincingly demonstrated that nab-paclitaxel in
combination with gemcitabine is an effective treatment regi-
men for metastatic pancreatic cancer [12, 13]. The pivotal
phase III study (MPACT) demonstrated clinical superiority
of a nab-p/gemcitabine combination over gemcitabine alone
with respect to ORR (23% vs. 7%), PFS (5.5 months vs.
3.7 months) and OS (8.7 months vs. 6.6 months) [12, 13].
Data of the MPACT trial indicated that nab-p/gemcitabine
may not be feasible in PDAC patients ≥75 years. However,
the MPACT trial lacked a geriatric assessment to properly
evaluate the health status and functional reserve of elderly
pancreatic cancer patients. In contrast, retrospective data
from routine clinical setting presented by Giordano et al.
[14] suggest similar benefits of (selected) elderly and young
patients from gemcitabine and nab-paclitaxel combination
therapy. However, to date it is not clear which elderly pa-
tients will benefit from intensified combination treatment
and how to select them.
This study is based on the hypothesis that personalized,
geriatric assessment directed treatment algorithms can
identify elderly patients, who benefit from nab-paclitaxel/
gemcitabine combination therapy. A stratified treatment
approach shall result in patient groups with a stable or im-
proving CGA performance during the first cycle of treat-
ment. As a result, more elderly patients may receive the
combined treatment in the future, who have so far been
excluded from such regimens due to an age cut-off. Con-
versely, a burdensome chemotherapy treatment may be
spared in vulnerable patients even though they might fall
into the appropriate age bracket.
Methods/design
Study design
This study is designed as a multicenter, open label,
phase IV interventional study to describe the impact
of comprehensive geriatric assessment (CGA) on the
course of treatment of elderly pancreatic cancer pa-
tients. CGA includes various tests and scoring sys-
tems (compare below) to stratify patients as
“GO-GO”, “SLOW-GO” or “FRAIL” patients. Depend-
ing on the test results, patients receive either chemo-
therapy (GO-GO group: nab-paclitaxel/gemcitabine;
SLOW-GO group: gemcitabine monotherapy) or best
supportive care (FRAIL group). After the first cycle of
chemotherapy (4 weeks) a subsequent CGA and a
safety assessment is performed to assess the primary
objective and assign patients to their definite treat-
ment arm (Fig. 1).
Study objectives
The primary objective is that CGA-stratified patients do
not decline in their CGA performance in response to
chemotherapy measured as a loss of five points or less in
the Barthel’s activities of daily living, (ADL1 vs. ADL2
during core CGA assessment). Thereby we aim to evalu-
ate if treatment stratification by CGA leads to identifica-
tion of those elderly patients, who benefit from
combined nab-paclitaxel/gemcitabine therapy.
Secondary objectives
 Evaluation of the predictive value of the CGA (CGA
1 + 2) testing for the incidence of ≥ grade 3
hematological and/ or non-hematological toxicities;
 Predictive value of the assessed geriatric tests for
treatment discontinuation;
 Response rates;
 Safety (nab-p/gemcitabine combination and
gemcitabine alone);
 Survival rates including progression-free survival
(PFS) and overall survival (OS);
 Percentage of patients receiving therapy in each
treatment group;
 Percentage of patients improving in the CGA during
therapy;
 Quality of life (QoL) and time to QoL deterioration.
Measurements
CGAs will be performed before (during screening, all
treatment arms) and after the first chemotherapy cycle
(CGA 1 + 2). Patients in the FRAIL arm will be assessed
after 28 days for their 2nd CGA (CGA 2). Additional
CGAs are performed after the 3rd and 6th cycle of
chemotherapy and/or end of treatment. CGA 3 and 4 are
performed in parallel with tumor restaging procedures.
The ideal -albeit potentially unobtainable- time points for
CGAs (CGA 3 + 4) in the FRAIL patients are Day 84 (±
14 days) and Day 168 (± 14 days) respectively.
A full CGA comprises the following assessments tools:
 Functional tests include the Instrumental Activities
of Daily Living (IADL) according to Lawton/Browdy
[15] and the Activities of Daily Living (ADL,
Barthel’s index) [16].
 Screening tests include the G8-Questionaire [17]
and the non-hematological Chemotherapy Risk As-
sessment Scale for High-age patients (CRASH) to
assess toxicity [18];
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 Comorbidities are evaluated using the Charlson
Comorbidity Index [19];
 Mini mental state examinations (MMSE) are
performed to assess cognitive deficiencies [20];
 The Geriatric Depression Scale 15 (GDS15) is
performed for analysis of affective co-morbidities [21];
 A nutritional assessment is done with the help of
mini nutritional assessment (MNA) [22];
 As biological test, the timed get up test (chair stand
test) is used [23];
 Finally, geriatric syndromes are evaluated by the
treating physician and a trained geriatric nurse.
Full CGA will only be performed during the screening/
baseline assessment (CGA1). Thereafter only the core
CGA is mandated for all following assessments, while all
additional assessment tools of the full CGA are optional.
CGA core assessment for treatment decision and escal-
ation during CGA1 and CGA2 consist of Eastern Co-
operative Oncology Group (ECOG) performance status,
ADL, IADL and G8-Questionnaire (Table 1).
Treatment assignment according to core CGA
Depending on the patients’ performance during the
baseline core CGA, patients are assigned to treatment as
shown in Table 1. Definitive assignment is going to be
confirmed by investigators decision.
After the first cycle of chemotherapy, the treatment
regimen will be re-assessed based on the results of the
2nd core CGA assessment. CGA improvement and treat-
ment related toxicity ≤ grade 1 according to CTC-criteria
can lead to cross over to the GO-GO or SLOW-GO arm
(escalation). The indication to escalate has to be con-
firmed by investigators decision. Of note, FRAIL subjects
that become eligible for a mono-chemotherapy are with-
drawn from the study and may commence any chemo-
therapy at the discretion of the treating physician. This is
owed to the less strict inclusion criteria of this observa-
tional cohort. Therefore, technically no treatment escal-
ation within this study from FRAIL to SLOW-GO is
permitted. A central CGA review is conducted by tele-
phone conference with the study investigator to relay
changes in the CGA2 results, in particular CGA differ-
ences that result in treatment modifications. In case of
toxicities to nab-paclitaxel or gemcitabine, schedules for
dose delay and dose modification will apply.
Fig. 1 Study scheme. Patients are stratified into three functional groups by comprehensive geriatric assessment and receive different intensity
treatments. After the first cycle, CGA is repeated and patients are attributed to their definitive treatment groups. The primary end point (decrease
of five points or less in Barthels ADL) is assessed by the second CGA
Table 1 Treatment assignment based on core CGA testing
GO-GO arm SLOW-GO arm FRAIL arm
ECOG 0–1 ≤ 2 ≥ 3
G8-Questionaire > 14 points ≤ 14 points < 14 points
ADL (Barthel) = 100 ≤ 100 < 100
IADL = 8 (f) / = 5 (m) ≤ 8 (f) / ≤ 5 (m) < 8 (f) / < 5 (m)
Betge et al. BMC Cancer  (2018) 18:747 Page 3 of 7
Primary and secondary end points
Primary endpoint
Evaluation of loss of five points or less in the Activity of
Daily Living (Barthel’s ADL) after first cycle of chemo-
therapy or after 4 weeks of best supportive care (BSC)
compared to the initial ADL for each treatment group.
Secondary endpoints
 CGA scores before and after 1st treatment cycle or
day 28 of BSC (CGA1 + 2; further CGA scores 3 + 4
– if available after 3rd and 6th cycle or D84 and




 Percentage of patients receiving at least one
chemotherapy in each treatment group and
percentage of patients escalating treatment;
 Duration of treatment
 Cumulative dose of administered chemotherapy
medication
 Quality of life (time to QoL deterioration, defined as
loss of 10 points in Quality of Life Questionaire C30
(QLQ-C30))
 Discrepancy between CGA strata estimation by the
investigator and true CGA assessment.
Data collection
Data for this study will be recorded via eCRF by the site
from the source documents according to standard oper-
ational procedures. Data are reviewed and checked for
omissions, apparent errors, and values requiring further
clarifications using computerized (automatic) and/or
manual procedures. Accurate and reliable data collection
will be assured by verification and cross–check of the
eCRF against the investigator’s records by the study
monitor. Data will be recorded and reported until the
last subject will have completed the trial.
Statistical analysis and sample size
Despite of the descriptive nature of this study with its
multiple CGA-driven decision processes, a formal statis-
tical testing is planned after the 1st chemotherapy cycle.
The primary endpoint will be analyzed separately in each
CGA-defined treatment arm (GOGO, SLOWGO, FRAIL).
Based on literature data it is assumed that without CGA
approximately 20% of patients will experience a functional
decline after the 1st chemotherapy cycle. With CGA this
rate is expected to be considerably decreased to about 6%
[8, 24]. Under this assumption it shall be shown with 80%
power at one-sided significance level alpha of 0.05 that the
proportion of patients with functional decline (Barthel’s
ADL) is less than 20%. Applying an exact one-sample test
for one binomial population, this requires the inclusion of
43 patients with a maximum number of 2 patients with
ADL decline per group. Accounting for an additional 5%
drop-out rate during the first treatment cycle, a total of
n = 45 patients are to be recruited into each treatment
arm. Hence, a total of 135 eligible patients will be enrolled
in this study. It is expected that this number of patients
can be recruited within 24 months by 6 sites in Germany.
Inclusion and exclusion criteria of the GO-GO /
SLOW-GO and FRAIL arms are shown in Table 2.
Study protocol
Our study protocol is in accordance with the SPIRIT
guidelines for reporting clinical trials. We included a sup-
plemental table containing a short study synopsis that in-
cludes all items from the World Health Organization
Trial Registration Data Set (Additional file 1: Table S1).
Approval
The GrantPax trial is an Arbeitsgemeinschaft Internis-
tische Onkologie (AIO) trial of the German Cancer Soci-
ety, approved by the working group geriatric oncology
(AIO-GER-0115). The study was approved by the Ethics
Committee II at Medical Faculty Mannheim, Heidelberg
University, Mannheim, Germany [2016-003F-MA], pro-
viding approval for all study sites in agreement with local
ethics committees. Written informed consent is obtained
from all participants. Amendments to the protocol have
to undergo approval from the applicable competent au-
thority and the ethics committees.
Trial status
GrantPax commenced recruitment in June 2016 and is
at the moment recruiting patients. We estimate comple-
tion of the study by June 2019.
Discussion
It is not clear which elderly pancreatic cancer patient
benefits from intensified combination treatment with gem-
citabine and nab-paclitaxel and how to select those pa-
tients. GrantPax is the first trial worldwide evaluating a
CGA-driven treatment allocation to personalize cancer
therapy for elderly patients with mPDAC. The aim is to
stratify patients into groups with different functional status
to allow patients to receive different intensities of treatment
(nab-paclitaxel/gemcitabine, gemcitabine monotherapy,
BSC). This personalization of treatment shall result in a
stable or improving functional performance, which is mea-
sured as a decrease in ADL of ≤5 points. Ultimately, this
may allow for more elderly patients to receive intensive
chemotherapy and thereby improve survival, but spare vul-
nerable patients a burdensome treatment. This approach
has been successfully tested in elderly patients with lung
cancer [2, 25].
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In routine practice, estimation of the functional capacity
of a patient depends on the experience and judgment of the
oncologist. This judgment seems to be fair in the majority
of cases, exemplified by the FOCUS2 trial, in which only
18% of colorectal cancer patients initially attributed to a
reduced-dose regimen by the oncologist could tolerate an
afterwards escalated dose regimen over longer time [26].
Nevertheless, the trial also exemplifies that there is a signifi-
cant number of elderly patients over-treated by standard
combination regimens, while there are certainly others that
are under-treated and withheld from chemotherapy due to
fear of enhanced side effects in elderly individuals. A stan-
dardized method for treatment allocation to elderly patients
is lacking. GrantPax is the first trial to prospectively ascer-
tain data on this matter in patients with pancreatic cancer.
Balducci and Extermann [6] defined three groups of eld-
erly patients: functionally independent patients without
co-morbidities that may receive standard cancer therapy,
intermediate patients who may benefit from reduced
chemotherapy and frail patients (dependent in activities of
daily living, comorbidities, geriatric syndromes) that are
candidates for best supportive care only [6]. Patients falling
in each of these categories can be designated as GOGO,
SLOWGO and FRAIL, respectively. A geriatric assessment
for all elderly cancer patients has been recommended by
different international societies but has not yet been imple-
mented in routine practice [10, 27, 28]. There is evidence
that geriatric assessments in oncology can support oncolo-
gist’s treatment decisions and improve patients’ quality of
life, management of toxicities and also overall survival.
However, previous studies were mainly small retrospective
analyses [29]. Data on elderly patients with pancreatic can-
cer are especially limited [30, 31]. Also, there are only lim-
ited data available yet on how the functional status of
elderly patients evolves under chemotherapy. Hoppe et al.
[8] observed a functional decline in 16,7% of 364 elderly pa-
tients receiving first line chemotherapy for different solid
tumors. Based on this data, the primary objective in our
study is to reach a stable functional status by treatment
stratification. A functional decline in less than 6% of pa-
tients was set as primary endpoint.
Currently, the safety and efficacy of dose-adjusted FOL-
FIRINOX in elderly patients with metastatic pancreatic
cancer is assessed in the phase II PAMELA-70 trial
(NCT02143219). Importantly, this trial evaluates the toler-
ance of the treatment by analysis of toxicity, but also by
decrease of the patients’ADL. However, a CGA or a strati-
fication of the patients by functional status is not included
in this trial. Regarding Gem/NabP combination therapy, a
retrospective analysis suggested that the combination was
effective in elderly patients and exhibited a different, but
tolerable toxicity profile [32, 33]. GrantPax prospectively
evaluates this combination in elderly patients using CGA
to stratify patients based on functional status.
To date, it is not clear which geriatric functional tests
should be performed for treatment allocation in mPDAC
patients receiving first line chemotherapy. The geriatric
core assessment in the GrantPax trial consists of the ADL/






Patients ≥70 years of age + +
Histologically or cytologically confirmed
metastatic adenocarcinoma of the
pancreas.
+ +
No prior chemotherapy (except fluoruracil
or gemcitabine in an adjuvant setting at
least > 6 months prior enrollment).
+ +
Cooperation and willingness to complete
all aspects of the study
+ +
Written informed consent to participate in
the study
+ +
At least one measurable lesion of disease
according to RECIST 1.1 criteria.
+
Adequate end organ function (renal
function: serum creatinine ≤1.5 × ULN or
GFR≥30mL/min, hematopoietic function:
white blood cell (WBC) count ≥3000/μL,
absolute neutrophil count (ANC)≥1500/μL,
platelets ≥105/μL, hemoglobin level>9.0g/
dL, liver function: total bilirubin ≤1.5 ×
ULN, AST / ALT ≤3.0 × ULN)
+
Exclusion criteria
Patient has received any other
investigational product within 28days prior
study entry
+ +
Patient is < 5years free of another primary
malignancy (except: not currently clinically
significant nor requiring active
intervention)
+ +
Patient with any significant history of non-
compliance to medical regimens or with
inability to grant reliable informed consent
+ +
Any psychiatric illness that would affect
the patient’s ability to understand the
demands of the clinical trial
+ +
Parallel participation in another clinical
trial or participation in another clinical trial
within the last 30days or 7 half-lifes of a
study medication, whichever is of longer
duration, prior study start
+ +
Patient has a severe and/or uncontrolled
medical disease (i.e. uncontrolled active
infection, uncontrolled hypertension/
diabetes or cardiac disease).
+
Hypersensitivity against gemcitabine or
nab-paclitaxel.
+
Major surgery ≤28 days prior to study
entry.
+
Patient has a known diagnosis of human
immunodeficiency virus (HIV) infection.
+
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IADL, the G8 questionnaire and ECOG performance sta-
tus. ADL and IADL are the most commonly used func-
tional tests in geriatrics, ECOG is well known and
established among oncologists. G8 is a screening tool that
is recommended by consensus statements and has prog-
nostic relevance [9, 10], however, no data are yet available
on changes of the G8 score (and other geriatric tests) dur-
ing chemotherapy in patients with mPDAC.
A potential problem regarding CGAs is the known
inter-observer variability of ADL and IADL. We aim to
minimize this problem by letting the same observer per-
form the CGA in each study center. Furthermore, there
are no official cut-off values to discriminate between
GOGO and SLOWGO or SLOWGO and FRAIL, poten-
tially leading to overlaps and inconclusive classifications.
Cut-off values exist for the G8, but not for ADL or
IADL. Therefore, the final classification into one of the
arms is the investigators decision.
A CGA is time consuming and therefore expensive, it is
therefore questionable if it can be performed in routine
practice. In the future, a condensed assessment with pa-
tient reports may be most practical. The GrantPax trial
will evaluate which geriatric tests and screening tools are
of the best predictive value with its secondary end points.
In conclusion, Grantpax is the first trial to evaluate
the impact of a CGA based treatment stratification on
functional decline of elderly pancreatic cancer patients
under chemotherapy.
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